Bemnifosbuvir Sulfate
Treatment of hepatitis C virus (HCV) infection
- CAS No.
- 2241337-84-6
- Indication Class
- Anti-infectives
- Patent Expiry
- To be assessed
- Therapeutic Area
- Antiviral / Hepatitis
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- Candidate (In-research)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An NS5B nucleotide analog with pangenotypic activity and a high resistance barrier, an important component of HCV combination and retreatment regimens.
Antiviral / Hepatitis · In research; suited to co-development
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Bemnifosbuvir is an investigational drug under development, primarily investigated for the treatment of hepatitis C virus (HCV) infection. It belongs to the class of NS5B polymerase inhibitors, which work by inhibiting viral replication, thereby aiding in the control and management of the infection.
Supply source: Unibest · Bemnifosbuvir Sulfate, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.